tbuckley/cabot-search huggingface dataset:
Unless we address the inequity in global health, then the world will not be prepared for the next pandemic
Authors: Ayoade Olatunbosun-Alakija
Journal: BMJ (2021)

The global health infrastructure is broken. We are attempting to put plasters on multiple compound fractures—a useless and wasteful exercise. This failure to act is not about resources, or a lack thereof, but rather a deep inequality in society, one which predates this current pandemic. It is the lynchpin that has brought us to our knees. The suggestion that there is a lack of vaccines or tools to adequately address the pandemic worldwide is a myth perpetuated by the global North in order to avoid taking accountability for the hoarding and price gouging of vaccines. We exist in a divided world, one which is continuing to fragment along the lines of bias and inequity. Enough is enough.

There is an urgency for world leaders to take responsibility for the systemic change required to achieve global pandemic preparedness and bring an end to this ongoing covid-19 humanitarian …
Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix
Authors: Kyle H Vining, Anna E. Marneth, Kwasi Adu-Berchie, Christina M. Tringides, Joshua M Grolman, Yutong Liu, Waihay J. Wong, Olga Pozdnyakova, Mariano Severgnini, Alexander Stafford, Georg N. Duda, Ann Mullally, Kai W. Wucherpfennig, David J Mooney
Journal: Blood (2021)
Immunodynamics of Paroxysmal Nocturnal Hemoglobinuria
Authors: Carmelo Gurnari, Simona Pagliuca, Adam Wahida, Tariq Kewan, Waled Bahaj, Minako Mori, Bhumika J. Patel, Kewal Asosingh, Valeria Visconte, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML)
Authors: Catia Patricia Simoes, Carmen Chillon, David Martínez-Cuadrón, María José Calasanz, María-Belén Vidriales, Iria Vazquez, Montserrat Hernández-Ruano, Beñat Ariceta, Leire Burgos, Diego Alignani, Sarvide Sarai, Sara Villar, Felipe Prósper, Rosa Ayala, Joaquín Martínez-Lopez, Juan Miguel Bergua Burgues, Susana Vives, Jose A. Perez-Simon, María García-Fortes, Marcos González, Jesus San-Miguel, Miguel A. Sanz, Pau Montesinos, Bruno Paiva
Journal: Blood (2021)
49 Highly multiplexed detection of critical immune checkpoints and immune cell subtypes in cancerous FFPE tissues using CODEX
Authors: Olive Shang, Judi Gordon, Nadya Nikulina, Sejal Mistry, Jasmine Singh, Hailing Zong, Jessica Yuan, Trillium Blackmer, Darren Locke, Oliver Braubach, Julia Kennedy-Darling, Peter Miller
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background There is growing consensus that spatial biology is the key to unlocking the underlying mechanisms of cancer immunotherapy and to predicting patient outcomes. Indeed, a recent example using the Akoya Phenoptics technology revealed a unique phenotypic signature of CD8/Foxp3 positive cells embedded within the tumor microenvironment of patients that responded favorably to PD-1 checkpoint inhibition. 1 In this case, the combination of both multiparameter and spatial readouts was required to correlate significantly with outcome. As the number of treatment options expands and knowledge regarding cell types that contribute to treatment mechanisms improves, so too do the number of markers required to analyze responses that enable discovery of new signatures. Methods Here, we present data from the analysis of human FFPE cancer tissues using an expanded CODEX antibody catalog targeting a variety of immune, immune checkpoint and transcription factors. CODEX enables the highly multiplexed detection of more than 40 targets within the same tissue sample, with single cell resolution and without degradation of the sample. Results Our expanded target list enables detection of key macrophage populations, T and B cell subtypes, granulocytes, dendritic cells, natural killer cells, stromal, tumor and epithelial cells. Additionally, the activation state of these immune and tumor cell types can be measured through detection of key immune checkpoints, including PD-1 and PD-L1. Through the addition of these critical markers, both cells known to contribute to treatment outcome and new biomarker signatures can be identified. Conclusions Continued expansion of spatial biology discovery capabilities will be critical to continuing to improve patient outcomes and to develop new treatment options of solid tumors using cancer immunotherapies. Reference Berry S, Taube J, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science . 2021; 372: 6547.
Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma
Authors: Alex F. Herrera, Tamer Othman, Paul Frankel, Pamela Allen, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V. Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T. Rosen, Elad Sharon, Joseph M Tuscano
Journal: Blood (2021)
Abstract 9162: Increased Ratio of B2/B1-like Lymphocytes in the Perivascular Adipose Tissue Could Contribute to Plaque Destabilization in Human Coronary Arteries: Preliminary Results
Authors: Daniela S Farias-itao, Carlos Augusto Pasqualucci, Renato A Andrade, Luiz Fernando F da Silva, Maristella Y Estevam, Alexandre B Campo, Claudia K Suemoto
Journal: Circulation (2021)

Introduction: B-lymphocyte density in the pericoronary adipose tissue (PvAT) was correlated with plaque size in human coronary arteries. However, the subtypes of B cells in the PvAT and atherosclerotic plaque composition have not investigated yet. Hypothesis: We hypothesized that B2 and the ratio of B2/B1-like lymphocytes in the PvAT will correlate with an increase in components related to plaque destabilization and a decrease in components related to plaque stabilization. B1-like lymphocytes will correlate with an increase of components related to plaque stabilization. Methods: Coronary arteries were freshly dissected with adjacent PvAT. The most important atherosclerotic plaque was selected from each main coronary artery. From 107 artery segments, we calculated the percentage of arterial obstruction, intima-media thickness, the minimum fibrous cap thickness, and the percentage of collagen, smooth muscle cells, fibrous cap, calcification, lipid, necrosis, and intraplaque hemorrhage. We considered B2-lymphocytes as CD20 + CD43 - and B1-like lymphocytes as CD20 + CD43 + using the immunohistochemistry double staining technique. The densities of B2, B1-like, and the ratio of B2/B1-like lymphocytes were correlated with plaque composition using linear, negative binomial, or Poisson regressions models with clustering for multiple measures in the same individual and adjusted for age, sex, hypertension, diabetes, body mass index, sedentary lifestyle, smoking, and alcohol consumption. Results: B2 and B1-like lymphocyte density in the PvAT were not correlated with plaque components. However, the increase of the ratio of B2/B1-like lymphocytes was associated with a decrease in intraplaque collagen (β= -0.19, 95%CI= -0.35; -0.03, p=0.01), calcification (β= -0.15, 95%CI= -0.28; -0.02, p=0.01), hemorrhage (β= -0.08, 95%CI= -0.15; -0.02, p=0.009), minimum fibrous cap thickness (β= -0.03, 95%CI= -0.04; -0.01, p&lt;0.001), and an increase in the number of vasa vasorum in adventitia layer (β= 0.006, 95%CI=0.001; 0.01, p=0.006). Conclusions: An increase in the ratio of B2/B1-like lymphocytes in the PvAT could contribute to plaque destabilization by the decrease of atherosclerotic plaque components related to plaque stabilization.
A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT)
Authors: Madiha Iqbal, Felipe Andres Mendieta Nieto, Kaitlyn M Brannick, Zhuo Li, Hemant S. Murthy, James M. Foran, Vivek Roy, Mohamed A. Kharfan-Dabaja, Ernesto Ayala
Journal: Blood (2021)
31 Serum LAG-3 is associated with improved patient prognosis in high grade serous ovarian cancer
Authors: Nicole James, Katrin Eurich, Erin Lips, Payton De La Cruz, Morgan Woodman, Jennifer Ribeiro
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background High grade serous ovarian cancer (HGSOC) is a lethal gynecologic malignancy with a five-year survival rate of only 39 percent. 1 Despite the fact that ovarian tumors are considered immunologic, HGSOC patients respond poorly to PD-1 based immunotherapy. Hence, the need to identify novel prognostic and therapeutic immunologic factors is crucial. Our previous investigation uncovered intratumoral levels of immune co-inhibitory receptor LAG-3 as a marker of improved HGSOC patient survival. For this current study we sought to evaluate the prognostic utility of serum-based LAG-3, as well as determine how these circulating levels change in response to HGSOC standard of care therapy. Methods This study was approved by the Women and Infants Institutional Review Board; approval number 1057626. HGSOC serum samples were obtained from the Department of Special Testing and the Program in Women’s Oncology Gynecologic Tissue Bank at Women and Infants Hospital. A total of 43 HGSOC treatment naïve serum samples were tested for serum LAG-3 and in 20 of these patients, samples from on- and post- frontline platinum-based chemotherapy were also analyzed. A commercially available ELISA kit was employed to detect serum LAG-3. Results There was no statistically significant change in pre-, on-, and post- serum LAG-3 levels following frontline chemotherapy, however median levels of LAG-3 decreased once patients initiated therapy and remained stable post-treatment. Spearman Rank Correlation analysis revealed a significant relationship between progression-free survival (PFS) and pre-treatment serum LAG-3 levels (r=0.36, p=0.017). Furthermore, it was found that patients with a PFS of 6 months or less exhibited a significantly (p=0.0031) lower mean rank of pre-treatment serum LAG-3 levels, compared to patients with a PFS of 18 months or longer. Finally, Kaplan Meier curve analysis revealed a statistically significant association between longer patient PFS and higher pre-treatment LAG-3 concentrations, when stratified by both median(HR=0.4916, log-rank p=0.022) and quartile LAG-3 serum levels (HR=0.2679, log-rank p=0.0031). Conclusions This study demonstrates for the first time that circulating immune checkpoint receptors have prognostic capabilities in ovarian cancer. Our findings suggest that LAG-3 is a marker for improved patient PFS. Future directions include an expansion of this original cohort in order to validate and further assess the clinical prognostic utility of serum LAG-3 in HGSOC. Reference Survival Rates for Ovarian Cancer, American Cancer Society, [https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html]
Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and <i>DDX41</i> Mutation: Mayo Clinic Experience
Authors: Ahmad Nanaa, Aref Al-Kali, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Z. Sproat, Rong He, Phuong L Nguyen, Dragan Jevremovic, Mohamed E Salama, Patricia Greipp, Naseema Gangat, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun V. Shah, Mrinal M. Patnaik, Hassan B. Alkhateeb
Journal: Blood (2021)
Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
Authors: Katrin Reutter, Sarah Sandmann, Jonas Rohde, Stephanie Müller, Marius Wöste, Tasneem Khanam, Ulf Michgehl, Wolfram Klapper, Wilhelm Wößmann, Jochen Seggewiß, Georg Lenz, Martin Dugas, Birgit Burkhardt
Journal: Leukemia (2021)
The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma
Authors: Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun
Journal: Blood (2021)
Myeloid Sarcoma Reveals a Unique Tumor Micro-Environment and Differential Prognosis Based on Transplant Status and Type of Treatment Received
Authors: Yazan Numan, Hamza Tariq, Jie Fan, Ping Xie, Madelyn Burkart, Yasmin Abaza, Yi-Hua Chen, Shira Dinner, Olga Frankfurt, Jayesh Mehta, Hui Zhang, Jessica K. Altman, Bin Zhang
Journal: Blood (2021)
Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting
Authors: Andrius Zucenka, Vilmantė Vaitekėnaitė, Kazimieras Maneikis, Regina Pileckytė, Igoris Trociukas, Valdas Pečeliūnas, Laimonas Griškevičius
Journal: Blood (2021)
Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis
Authors: Guru Subramanian Guru Murthy, Brent R. Logan, Stephanie Bo-Subait, Amer Beitingjaneh, Steven Devine, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A. Yared, Heather E. Stefanski, Michael A. Pulsipher, Jack W. Hsu, Galen E. Switzer, Sandhya R. Panch, Bronwen E. Shaw
Journal: Blood (2021)
Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes
Authors: Allison M. Bock, Raphael Mwangi, Matthew J. Maurer, Nora Bennani, David J. Inwards, James R. Cerhan, Thomas E. Witzig, Thomas M. Habermann, Yucai Wang, Grzegorz S. Nowakowski
Journal: Blood (2021)
The roles of exosomal immune checkpoint proteins in tumors
Authors: Cheng Xing, Heng Li, Rui-Juan Li, Le Yin, Hui-Fang Zhang, Zi-Neng Huang, Zhao Cheng, Ji Li, Zhi-Hua Wang, Hong-Ling Peng
Journal: Military Medical Research (2021)

Abstract Targeting immune checkpoints has achieved great therapeutic effects in the treatment of early-stage tumors. However, most patients develop adaptive resistance to this therapy. The latest evidence demonstrates that tumor-derived exosomes may play a key role in systemic immune suppression and tumor progression. In this article, we highlight the role of exosomal immune checkpoint proteins in tumor immunity, with an emphasis on programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), as well as emerging evidence on roles of T cell immunoglobulin-3 (TIM-3), arginase 1 (ARG1), and estrogen receptor binding fragment-associated antigen 9 (EBAG9) expressed by exosomes.
Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies
Authors: Eugene Choi, Jae-Woong Chang, Joshua Krueger, Walker S Lahr, Emily Pomeroy, Meghan Walsh, Annie Khamhoung, Jennifer Johnson, Charlotte Franco, Lukasz Swiech, Simarjot Pabla, Celeste Richardson, Vipin Suri, Beau R Webber, Branden S Moriarity
Journal: Blood (2021)
Specific T Cell Receptor Gene Repertoire Profiles in Subgroups of CLL Patients with Distinct Genomic Aberrations
Authors: Elisavet Vlachonikola, Electra Sofou, Glykeria Gkoliou, Nikos Pechlivanis, Georgios Karakatsoulis, Sabine Jeromin, Niki Stavroyianni, Pamela Ranghetti, Lydia Scarfo, Cecilia Österholm-Corbascio, Larry Mansouri, Achilles Anagnostopoulos, Paolo Ghia, Claudia Haferlach, Richard Rosenquist, Fotis Psomopoulos, Kostas Stamatopoulos, Panagiotis Baliakas, Anastasia Chatzidimitriou
Journal: Blood (2021)
COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation
Authors: Giovanna Lucchini, Elena Cozma, Aimee Jackson, Kimberly Gilmour, Rachel Elizabeth Protheroe, Eleni Tholouli, Robert F Wynn, Keith Wilson, Karl S Peggs, Victoria Potter, Anne Parker, Charles Craddock, Shankara Paneesha, Emma Nicholson, David I. Marks, Oana Mirci-Danicar, Christopher Parrish, Alexander M Martin, Graham McIlroy, Rebecca Bishop, Rebecca Collings, Ellie Williams, Persis J Amrolia
Journal: Blood (2021)
The Von Willebrand Disease Aging and Bleeding Correlation (VWD ABC) Study
Authors: Craig D. Seaman, Margaret V. Ragni, Peter A. Kouides, Eric H. Kraut, Rajiv K. Pruthi, Leslie J. Raffini, Jonathan C. Roberts, Annette von Drygalski, Daniel B. Bellissimo, Maria M Brooks
Journal: Blood (2021)
End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas
Authors: Neha Mehta-Shah, Eric D Jacobsen, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, Amanda F. Cashen, Armin Ghobadi, Beth Reagan, Anne Fischer, Alison J. Moskowitz, Fei Wan, Austin Jacobsen, Meredith Olson, Edgar Vigil, Natalie Hill, Karina Elias, Ying Huang, Steven M. Horwitz
Journal: Blood (2021)
From the Cava to the Chest: Partial Anomalous Pulmonary Venous Connection
Authors: Hillary R. Johnson, Allison B. Couillard, Rebecca A. Busch, Micah T. Long
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"From the Cava to the Chest: Partial Anomalous Pulmonary Venous Connection." American Journal of Respiratory and Critical Care Medicine, 205(7), pp. e14–e15
RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort?
Authors: Olivier Decaux, Aurore Perrot, Laurent Frenzel, Bruno Royer, Carla Araujo, Karim Belhadj, Philippe Moreau, Denis Caillot, Xavier Leleu, Agathe Farge, Anne Vekhoff, Samantha Schulmann, Jean Fontan, Frederique Orsini, Laurence Sanhes, Valentine Richez, Arnaud Jaccard, Ronan Garlantezec, Nathalie Texier, Raphael Germain, Catherine Boccaccio, Cyrille Hulin
Journal: Blood (2021)
Safety and Efficacy of Tinostamustine in Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
Authors: Herve Ghesquieres, Antonio Pinto, Anna Sureda, Olivier Tournilhac, Franck Morschhauser, Tomas Janik, Pier Luigi Zinzani
Journal: Blood (2021)
Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Authors: Evangelos Eleutherakis Papaiakovou, Evangelos Terpos, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Panagiotis Malandrakis, Foteini Theodorakakou, Panagiotis Tsirigotis, Meletios-Athanasios Dimopoulos, Efstathios Kastritis
Journal: Blood (2021)
Covid-19: Pandemic reduced life expectancy in most developed countries, study finds
Authors: Matthew Limb
Journal: BMJ (2021)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Covid-19: Pandemic reduced life expectancy in most developed countries, study finds Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Authors: Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter
Journal: Blood (2021)
Multi-Recombinase Mouse Models of Flt3-Driven Leukemia Identifies Distinct Trajectories of Mutational Cooperativity and Leukemic Transformation
Authors: Robert L. Bowman, Tanmay Mishra, Shira E. Eisman, Louise Cai, Wenbin Xiao, Michael R. Waarts, Pablo Sanchez Vela, Inés Fernández-Maestre, Isabelle S. Csete, Chad R. Potts, Matthew T. Jenkins, Linde A. Miles, Jennifer J. Trowbridge, Paul Brent Ferrell, Ross L. Levine
Journal: Blood (2021)
Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin
Authors: Juliette Lambert, Pierre Peterlin, Cecile Pautas, Emmanuel Raffoux, Denis Caillot, Ollivier Legrand, Magalie Joris, Anna Berceanu, Jean Valere Malfuson, Sylvain Chantepie, Marc Bernard, Lauris Gastaud, Arnaud Pigneux, Omar Benbrahim, Caroline Bonmati, Hunault-Berger Mathilde, Hervé Dombret, Philippe Rousselot, Sylvie Chevret, Sylvie Castaigne
Journal: Blood (2021)
Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
Authors: Thomas A. Ollila, Rebecca Masel, John L Reagan, Kimberly Paiva, Shaolei Lu, Ralph Rogers, Adam Zayac, Rashida Taher, Inna Yakirevich, Rabin Niroula, Peter Barth, Adam J. Olszewski
Journal: Blood (2021)
External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland
Authors: Colin R Simpson, Chris Robertson, Steven Kerr, Ting Shi, Eleftheria Vasileiou, Emily Moore, Colin McCowan, Utkarsh Agrawal, Annemarie Docherty, Rachel Mulholland, Josie Murray, Lewis Duthie Ritchie, Jim McMenamin, Julia Hippisley-Cox, Aziz Sheikh
Journal: Thorax (2021)

Background The QCovid algorithm is a risk prediction tool that can be used to stratify individuals by risk of COVID-19 hospitalisation and mortality. Version 1 of the algorithm was trained using data covering 10.5 million patients in England in the period 24 January 2020 to 30 April 2020. We carried out an external validation of version 1 of the QCovid algorithm in Scotland. Methods We established a national COVID-19 data platform using individual level data for the population of Scotland (5.4 million residents). Primary care data were linked to reverse-transcription PCR (RT-PCR) virology testing, hospitalisation and mortality data. We assessed the performance of the QCovid algorithm in predicting COVID-19 hospitalisations and deaths in our dataset for two time periods matching the original study: 1 March 2020 to 30 April 2020, and 1 May 2020 to 30 June 2020. Results Our dataset comprised 5 384 819 individuals, representing 99% of the estimated population (5 463 300) resident in Scotland in 2020. The algorithm showed good calibration in the first period, but systematic overestimation of risk in the second period, prior to temporal recalibration. Harrell’s C for deaths in females and males in the first period was 0.95 (95% CI 0.94 to 0.95) and 0.93 (95% CI 0.92 to 0.93), respectively. Harrell’s C for hospitalisations in females and males in the first period was 0.81 (95% CI 0.80 to 0.82) and 0.82 (95% CI 0.81 to 0.82), respectively. Conclusions Version 1 of the QCovid algorithm showed high levels of discrimination in predicting the risk of COVID-19 hospitalisations and deaths in adults resident in Scotland for the original two time periods studied, but is likely to need ongoing recalibration prospectively.
GnRH neurons recruit astrocytes in infancy to facilitate network integration and sexual maturation
Authors: Giuliana Pellegrino, Marion Martin, Cécile Allet, Tori Lhomme, Sarah Geller, Delphine Franssen, Virginie Mansuy, Maria Manfredi-Lozano, Adrian Coutteau-Robles, Virginia Delli, S. Rasika, Danièle Mazur, Anne Loyens, Manuel Tena-Sempere, Juergen Siepmann, François P. Pralong, Philippe Ciofi, Gabriel Corfas, Anne-Simone Parent, Sergio R. Ojeda, Ariane Sharif, Vincent Prevot
Journal: Nature Neuroscience (2021)